#PharmaNews #EliLilly #NovoNordisk #ObesityTreatment #GLP1 #DrugInnovation #HealthcareTrends #PharmaceuticalIndustry #WeightLoss #LifeSciences To view or add a comment, sign in Regeneron Enters Obesity Drug Race With Zepbound-Like Results The obesity drug market is becoming one of the most competitive areas in pharma
Whether those effects translate directly to women in the GLP-1-therapy-plus-weight-loss context requires additional research that hasn't been published yet
Frequently Asked Questions Can you take retatrutide as a tablet or oral solution
Il existe galement des risques de base pour les fausses couches (soit 15 25 grossesses sur 100), pour laccouchement prmatur et pour dautres rsultats indsirables
And then the second one is, how safe are these compounded drugs
A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial